VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Down 24.4% in January

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 8,396 shares, a decrease of 24.4% from the December 31st total of 11,105 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 42,227 shares, the short-interest ratio is currently 0.2 days. Based on an average trading volume of 42,227 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the shares of the company are short sold.

Institutional Trading of VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. Institutional investors own 8.23% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

VivoSim Labs Stock Performance

VivoSim Labs stock traded up $1.22 during mid-day trading on Friday, hitting $2.92. 72,074,651 shares of the company traded hands, compared to its average volume of 1,100,603. VivoSim Labs has a one year low of $1.41 and a one year high of $21.96. The stock has a market cap of $7.62 million, a price-to-earnings ratio of -0.66 and a beta of 1.18. The stock has a fifty day moving average price of $2.06 and a 200-day moving average price of $2.36.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.98) earnings per share for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The company had revenue of $0.03 million for the quarter.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.